Agios Pharmaceuticals, Inc.

AGIO Healthcare Biotechnology

Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024. In the quarter to June 2026, revenue grew 259.3%, EPS grew 12.4% and free cash flow grew 25.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

31.32 1.00 −3.09%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
3/9
Altman Z
8.12
Beneish M
−1.72
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
942.05 965.60 833.84 832.77 1,064.23 636.68 611.70 613.78 445.26 559.89
Total non-current assets
355.17 697.60 103.28 405.95 373.51 216.28 279.04 244.68 169.14 59.20
Total Assets
1,297.23 1,663.20 937.12 1,238.72 1,437.74 852.95 890.74 858.46 614.40 619.09
Total current liabilities
82.21 81.16 67.96 62.63 59.83 94.39 92.89 93.50 94.94 88.43
Total non-current liabilities
21.91 41.09 58.14 75.28 85.94 359.06 157.33 77.42 143.95 172.07
Total liabilities
104.11 122.24 126.10 137.90 145.76 453.45 250.21 170.92 238.89 260.50
Common Equity (Total)
1,193.11 1,540.96 811.02 1,100.81 1,291.98 399.50 640.53 687.54 375.50 358.59
Shareholders Equity (Total)
1,193.11 1,540.96 811.02 1,100.81 1,291.98 399.50 640.53 687.54 375.50 358.59
Total Debt
— — — 72.00 0.28 0.33 0.67 — — —

Show all line items

In millions of $ except per-share values · columns are period end dates